Joint Regeneration Foundation Protocol

Reduce joint and connective-tissue inflammation, accelerate repair of tendon, ligament and capsular tissue, and restore pain-free range of motion after overuse or minor injury

Patient profile: Active adults with overuse joint pain (knee, shoulder, elbow, ankle), early tendinopathy, or minor ligament strain who want a peptide-naive-friendly entry protocol

Want a personalised protocol?

Our AI generator builds a protocol tailored to your profile and goals.

Generate protocol →

⚠️

This protocol is an educational example only. It does not apply to your specific health situation. Medical supervision is required. Peptide therapy is not approved by regulatory bodies for many of the described indications.

Protocol Stack

BPC-157

Primary

Dose

250–500 mcg

Frequency

1–2x/day SC

Timing

Morning (and optionally evening); inject SC proximal to the affected joint, not into the joint

Duration

8 weeks

TB-500 (Thymosin Beta-4)

Primary

Dose

2.5 mg

Frequency

2x/week SC (weeks 1–4), then 1x/week (weeks 5–8)

Timing

Any time; separate from BPC-157 by at least 2 hours

Duration

8 weeks

GHK-Cu

Supporting

Dose

1–2 mg SC

Frequency

1x/day SC (or topical 2% serum over the joint)

Timing

Evening

Duration

8 weeks

Monitoring Parameters

✓Pain score (NRS 0–10) at rest and at peak load — weekly
✓Active and passive range of motion — biweekly
✓Functional load test (single-leg squat, overhead reach, grip) — baseline, week 4, week 8
✓Swelling/effusion assessment — weekly
✓Adjunct: oral collagen peptides 10–15 g/day + vitamin C 500 mg taken together for substrate support

Expected Outcomes

Weeks 1–2: Reduced inflammatory pain, NRS typically declines 20–40%

Weeks 3–5: Improved load tolerance and range of motion, less morning stiffness

Weeks 6–8: Return to normal training/daily load with durable pain relief

Contraindications

✗Active malignancy (BPC-157 and TB-500 are pro-angiogenic and trophic)
✗Acute joint infection / septic arthritis — requires medical treatment first
✗Suspected complete tendon or ligament rupture — needs imaging and surgical assessment before peptide therapy
✗Known hypersensitivity to peptide components

Clinical Notes

This is the entry-level joint protocol and the foundation the two advanced joint protocols build on. BPC-157 and TB-500 are the core synergistic pair: BPC-157 acts locally via the nitric-oxide pathway, growth-factor upregulation (VEGF, EGR-1) and fibroblast migration, while TB-500 (Thymosin Beta-4) acts systemically through actin sequestration to drive cell migration and angiogenesis. For tendon and ligament work, BPC-157 is injected subcutaneously near (not into) the affected structure. GHK-Cu adds copper-dependent stimulation of collagen and glycosaminoglycan synthesis and helps balance matrix metalloproteinases. Oral collagen + vitamin C taken ~60 minutes before loaded rehab exercise is a well-supported, low-cost substrate adjunct. Peptides accelerate repair but do not replace progressive loading — keep doing appropriate rehab.

Case Study

Clinical Practice Example

Female, 42, recreational tennis player. Lateral epicondylitis (tennis elbow) of 6 months' duration, NRS 6/10 with grip, failed eccentric loading alone. Started BPC-157 300 mcg/day SC near the elbow + TB-500 2.5 mg 2x/week + GHK-Cu 1 mg/day, continued eccentric wrist-extensor loading. Week 3: grip pain 4/10, morning stiffness markedly reduced. Week 6: pain 1–2/10 at peak load, returned to full play. Week 8: NRS 0–1/10, grip strength symmetric with contralateral side. No adverse events.

← Back to all protocols